Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03268941 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)
A Phase 2 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT03268941 is a Phase 2 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 51 participants.
The verdict
NCT03268941, a Phase 2 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, PK and PD of TAK-906 in participants with Gastroparesis (GP).
Interventions
- DRUG TAK-906 Maleate
- DRUG Metaclopramide
- DRUG TAK-906 Maleate Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2017-09-26 |
| Est. Completion | 2018-03-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03268941
The ClinicalTrials.gov registry entry for NCT03268941 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which TAK-906 Maleate is the first listed.
NCT03268941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03268941 about?
NCT03268941 is a clinical study titled "A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)". The purpose of this study is to evaluate the safety, PK and PD of TAK-906 in participants with Gastroparesis (GP).
What is the current status of trial NCT03268941?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2017-09-26. Estimated completion is 2018-03-09.
What interventions are being tested in trial NCT03268941?
The interventions under investigation include: TAK-906 Maleate (DRUG), Metaclopramide (DRUG), TAK-906 Maleate Placebo (DRUG).
Who is sponsoring clinical trial NCT03268941?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.